More than 50% of breast cancer cases are estrogen-dependent, and treatment with estrogen antagonists that inhibit estrogen receptor (ER) action, particularly tamoxifen, has contributed to a dramatic reduction in breast cancer mortality. Here, ESR1 is linked to breast cancer.